Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb

Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, comments on the efficacy and toxicity profile of bispecific antibodies for multiple myeloma including teclistamab and elranatamab, discussing overall response rates (ORR), cytokine release syndrome (CRS) and infections. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.